JMP keeps Align at market perform

Align Technology, Inc. maintained its market outperform rating by JMP Securities analyst Anthony Ostrea on news that the company's U.S. ITC litigation against OrthoClear is moving forward as expected. JMP remains on the sidelines given the uncertainty in the outcome of the case and particularly since OrthoClear appears to be competing well against Align in the market. Shares of the Santa Clara, Calif., dental products manufacturing company were down 16 cents, or 1.90%, at $8.25 on volume of 635,291 shares versus the three-month running average of 764,725 shares. (Nasdaq: ALGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.